A growing number of monoclonal antibodies are being developed for the treatment of malignancies, transplant rejection, autoimmune and other immune disorders; however, they can have severe side effects. Hansel and colleagues consider the mechanisms underlying these effects and strategies to minimize them during preclinical screening and in first-in-human trials.
- Trevor T. Hansel
- Harald Kropshofer
- Andrew J. T. George
